The National Institutes of Health (NIH) is offering a funding opportunity titled "New Therapeutic Strategies for Genital Herpes" under the R21/R33 Clinical Trial Not Allowed mechanism. This initiative aims to stimulate research into innovative treatments that suppress virus shedding, minimize lesion formation, and reduce transmission risks associated with genital herpes, focusing on the development of new antivirals, therapeutic vaccines, and gene editing technologies. With a total budget of $3.5 million planned to support 7-10 grants, eligible applicants include a wide range of organizations such as academic institutions, nonprofits, and local governments. Interested parties must submit their applications by January 31, 2025, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.